---
granola_id: 3a9b83da-6e2a-4aee-ba2b-838913f20d72
title: "Yury Goltsev and Virtue"
type: note
created: 2025-04-29T16:29:56.833Z
updated: 2025-04-29T16:52:08.972Z
attendees:
  - yury@cellformatica.com
  - sd@virtuevc.com
  - dan@cellformatica.com
  - gdanfx@gmail.com
---
### Company Overview & Team Background

- Cellformatica - AI/bioinformatics company transitioning from no-code platform to target discovery
- Led by Yury Goltsev (CEO, serial entrepreneur)
	- Previously founded company in spatial biology (acquired by Sensus, went IPO 2021)
	- Currently maintains position at Stanford (Gary Nolanâ€™s lab)
- Co-founder is physician scientist from UPenn (pathologist, tumor immunology expert)

### Product & Technology

- Two main tools:
	- CFT Mate: Automatic data scientist tool deployed locally for security
		- Allows non-coders to analyze data through conversational interface
		- Creates code, plots, and compliance notebooks
	- Formatica: SaaS platform
		- Processes large target lists
		- Denoises data and generates insights
		- ~100+ current users

### Traction & Market Position

- Current customers include:
	- Schrodinger (drug discovery pharma)
	- Caliber (pharma inside script institute)
- Market opportunity:
	- Target market: 70,000 BSL labs
	- Drug discovery market ~$100B
	- $2B annual TAM for platform
- Already developed companion diagnostic for CAR T cell therapy (in IP development)

### Funding & Strategy

- Seeking funding round (~$1M)
- 18-24 month runway target
- Strategic transition:
	- Current: SaaS/software company
	- 2-year plan: Transition to lead generation/pharma company
	- Following model similar to Isomorphic Labs

### Next Steps

- Stay in touch regarding future fundraising
- Continue discussion when company gears up for raise

Chat with meeting transcript: https://notes.granola.ai/d/3a9b83da-6e2a-4aee-ba2b-838913f20d72
